Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects

Completed · Phase 4 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

This study is not being conducted in the United States. To investigate the relative efficacy of pimecrolimus cream 1% applied twice daily (b.i.d.) versus once daily (o.d.) in preventing the progression to disease "relapse".

Key facts

Study ID

NCT00139581

Run by

Novartis

Starts

2004-09-01

Expected to finish

2005-09-01

Last updated by the study team

2008-04-23

Who can join

Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

• This study is not being conducted in the United States — Novartis Pharma AG, Basel, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.